Givinostat’s Exclusive Distribution Agreement in 17 Central and Eastern European Countries, Including the Baltic States, has been Announced by Italfarmaco and Medis
Italfarmaco and Medis, a leading pharmaceutical commercialisation company in Central and Eastern Europe, today announced an exclusive distribution agreement for Givinostat (Duvyzat), Italfarmaco’s drug...
Biophytis’ BIO101 Therapy for Treatment of Sarcopenia Could Bring Hope to Duchenne Muscular Dystrophy Patients
The Phase 2 clinical trial SARA-INT was published in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the primary reference journal for sarcopenia research,...
Eteplirsen (Exondys 51) Treatment Significantly Slows Heart Function Decline in Duchenne Muscular Dystrophy
Following promising results in slowing heart function decline in patients with DMD, Eteplirsen (Exondys 51) continues to show potential in addressing key aspects of...
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Positive long-term results from the company's ongoing HOPE-2 open label extension ("OLE") clinical trial were announced today by Capricor Therapeutics, a biotechnology company that...
ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
Today, Italfarmaco's U.S. affiliate, ITF Therapeutics LLC, announced seven abstracts for the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas, March...